In­cyte hit by CRL on ex­tend­ed-re­lease JAK tablets, mud­dy­ing plans for Jakafi fran­chise ex­pan­sion

The FDA has re­ject­ed In­cyte’s ex­tend­ed-re­lease for­mu­la­tion of rux­oli­tinib tablets, in a sur­prise set­back for the com­pa­ny’s plans to build on its block­buster Jakafi fran­chise …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.